Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 504831, 11 pages
http://dx.doi.org/10.1155/2015/504831
Review Article

Current and Emerging Cell Culture Manufacturing Technologies for Influenza Vaccines

Department of Bioengineeringt, McGill University, Macdonald Engineering Building, 817 Sherbrooke Street W, Montreal, QC, Canada H3A 0C3

Received 3 December 2014; Revised 5 February 2015; Accepted 16 February 2015

Academic Editor: Gregory Tannock

Copyright © 2015 Ernest Milián and Amine A. Kamen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Palese, “The genes of influenza virus,” Cell, vol. 10, no. 1, pp. 1–10, 1977. View at Publisher · View at Google Scholar · View at Scopus
  2. W. Chen, P. A. Calvo, D. Malide et al., “A novel influenza A virus mitochondrial protein that induces cell death,” Nature Medicine, vol. 7, no. 12, pp. 1306–1312, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. H. M. Wise, A. Foeglein, J. Sun et al., “A complicated message: identification of a novel PB1-related protein translated from influenza A virus segment 2 mRNA,” Journal of Virology, vol. 83, no. 16, pp. 8021–8031, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. B. W. Jagger, H. M. Wise, J. C. Kash et al., “An overlapping protein-coding region in influenza A virus segment 3 modulates the host response,” Science, vol. 337, no. 6091, pp. 199–204, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Muramoto, T. Noda, E. Kawakami, R. Akkina, and Y. Kawaokaa, “Identification of novel influenza A virus proteins translated from PA mRNA,” Journal of Virology, vol. 87, no. 5, pp. 2455–2462, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Tong, Y. Li, P. Rivailler et al., “A distinct lineage of influenza A virus from bats,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 11, pp. 4269–4274, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Yamashita, M. Krystal, W. M. Fitch, and P. Palese, “Influenza B virus evolution: co-circulating lineages and comparison of evolutionary pattern with those of influenza A and C viruses,” Virology, vol. 163, no. 1, pp. 112–122, 1988. View at Publisher · View at Google Scholar · View at Scopus
  8. A. J. Caton, G. G. Brownlee, J. W. Yewdell, and W. Gerhard, “The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype),” Cell, vol. 31, no. 2, pp. 417–427, 1982. View at Google Scholar · View at Scopus
  9. A. J. Hay, V. Gregory, A. R. Douglas, and P. L. Yi, “The evolution of human influenza viruses,” Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 356, no. 1416, pp. 1861–1870, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. J. K. Taubenberger and J. C. Kash, “Influenza virus evolution, host adaptation, and pandemic formation,” Cell Host and Microbe, vol. 7, no. 6, pp. 440–451, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. P. D. Minor, O. G. Engelhardt, J. M. Wood et al., “Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK,” Vaccine, vol. 27, no. 22, pp. 2907–2913, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Verma, P. Khanna, and S. Chawla, “Influenza vaccine: an effective preventive vaccine for developing countries,” Human Vaccines and Immunotherapeutics, vol. 8, no. 5, pp. 675–678, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. A. H. Ellebedy and R. J. Webby, “Influenza vaccines,” Vaccine, vol. 27, supplement 4, pp. D65–D68, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. D. P. Greenberg, C. A. Robertson, M. J. Noss, M. M. Blatter, R. Biedenbender, and M. D. Decker, “Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults,” Vaccine, vol. 31, no. 5, pp. 770–776, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Stöhr, “Influenza vaccine production,” in Textbook of Influenza, pp. 352–370, John Wiley & Sons, 2013. View at Google Scholar
  16. FDA full prescribing information FluMist, http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM123743.pdf.
  17. R. A. Webster, R. G. Monto, A. S. Braciale, and T. J. Lamb, Textbook of Influenza, John Wiley & Sons, Oxford, UK, 2013.
  18. J. B. Ulmer, U. Valley, and R. Rappuoli, “Vaccine manufacturing: challenges and solutions,” Nature Biotechnology, vol. 24, no. 11, pp. 1377–1383, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. G. I. Alexandrova, G. N. Budilovsky, T. A. Koval et al., “Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial,” Vaccine, vol. 4, no. 2, pp. 114–118, 1986. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Z. Ghendon, F. I. Polezhaev, K. V. Lisovskaya, T. E. Medvedeva, G. I. Alexandrova, and A. I. Klimov, “Recombinant cold-adapted attenuated influenza A vaccines for use in children: molecular genetic analysis of the cold-adapted donor and recombinants,” Infection and Immunity, vol. 44, no. 3, pp. 730–733, 1984. View at Google Scholar · View at Scopus
  21. J. Partridge and M. P. Kieny, “Global production capacity of seasonal influenza vaccine in 2011,” Vaccine, vol. 31, no. 5, pp. 728–731, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. S.-S. Wong and R. J. Webby, “Traditional and new influenza vaccines,” Clinical Microbiology Reviews, vol. 26, no. 3, pp. 476–492, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. P. R. Dormitzer, T. F. Tsai, and G. Del Giudice, “New technologies for influenza vaccines,” Human Vaccines and Immunotherapeutics, vol. 8, no. 1, pp. 45–58, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Hilleringmann, B. Jobst, and B. C. Baudner, “Influenza cell-culture vaccine production,” in Molecular Vaccines, M. Giese, Ed., pp. 823–837, Springer International Publishing, Cham, Switzerland, 2014. View at Publisher · View at Google Scholar
  25. C. T. Hardy, S. A. Young, R. G. Webster, C. W. Naeve, and R. J. Owens, “Egg fluids and cells of the chorioallantoic membrane of embryonated chicken eggs can select different variants of influenza A (H3N2) viruses,” Virology, vol. 211, no. 1, pp. 302–306, 1995. View at Publisher · View at Google Scholar · View at Scopus
  26. J. S. Robertson, J. S. Bootman, R. Newman et al., “Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus,” Virology, vol. 160, no. 1, pp. 31–37, 1987. View at Publisher · View at Google Scholar · View at Scopus
  27. J. S. Robertson, P. Cook, A.-M. Attwell, and S. P. Williams, “Replicative advantage in tissue culture of egg-adapted influenza virus over tissue-culture derived virus: implications for vaccine manufacture,” Vaccine, vol. 13, no. 16, pp. 1583–1588, 1995. View at Publisher · View at Google Scholar · View at Scopus
  28. K. S. Reisinger, S. L. Block, A. Izu, N. Groth, and S. J. Holmes, “Subunit Influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity,” Journal of Infectious Diseases, vol. 200, no. 6, pp. 849–857, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Bardiya and J. H. Bae, “Influenza vaccines: recent advances in production technologies,” Applied Microbiology and Biotechnology, vol. 67, no. 3, pp. 299–305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. J. M. Katz, C. W. Naeve, and R. G. Webster, “Host cell-mediated variation in H3N2 influenza viruses,” Virology, vol. 156, no. 2, pp. 386–395, 1987. View at Publisher · View at Google Scholar · View at Scopus
  31. J. M. Katz and R. G. Webster, “Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs,” Journal of Infectious Diseases, vol. 160, no. 2, pp. 191–198, 1989. View at Publisher · View at Google Scholar · View at Scopus
  32. W. J. Meyer, J. M. Wood, D. Major, J. S. Robertson, R. G. Webster, and J. M. Katz, “Influence of host cell-mediated variation on the international surveillance of influenza A (H3N2) viruses,” Virology, vol. 196, no. 1, pp. 130–137, 1993. View at Publisher · View at Google Scholar · View at Scopus
  33. WHO, Process of Influenza Vaccine Virus Selection and Development, World Health Organization, 2007.
  34. E. D. Kilbourne, “Future influenza vaccines and the use of genetic recombinants,” Bulletin of the World Health Organization, vol. 41, no. 3, pp. 643–645, 1969. View at Google Scholar · View at Scopus
  35. E. Fodor, L. Devenish, O. G. Engelhardt, P. Palese, G. G. Brownlee, and A. García-Sastre, “Rescue of influenza A virus from recombinant DNA,” Journal of Virology, vol. 73, no. 11, pp. 9679–9682, 1999. View at Google Scholar · View at Scopus
  36. G. Neumann, T. Watanabe, H. Ito et al., “Generation of influenza A viruses entirely from cloned cDNAs,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 16, pp. 9345–9350, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Hoffmann, G. Neumann, Y. Kawaoka, G. Hobom, and R. G. Webster, “A DNA transfection system for generation of influenza A virus from eight plasmids,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 11, pp. 6108–6113, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. O. G. Engelhardt, “Many ways to make an influenza virus—review of influenza virus reverse genetics methods,” Influenza and other Respiratory Viruses, vol. 7, no. 3, pp. 249–256, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Ye, J. G. Evans, and J. Stambas, “Influenza reverse genetics: dissecting immunity and pathogenesis,” Expert Reviews in Molecular Medicine, vol. 16, article e2, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. R. J. Webby, D. R. Perez, J. S. Coleman et al., “Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines,” The Lancet, vol. 363, no. 9415, pp. 1099–1103, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Nicolson, D. Major, J. M. Wood, and J. S. Robertson, “Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system,” Vaccine, vol. 23, no. 22, pp. 2943–2952, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. WHO, Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza, World Health Organization, Geneva, Switzerland, 2011.
  43. P. Dormitzer, “Cell culture-derived influenza vaccines,” in Influenza Vaccines for the Future, R. Rappuoli and G. Del Giudice, Eds., pp. 293–312, Springer, Basel, Switzerland, 2011. View at Google Scholar
  44. C. Gerdil, “The annual production cycle for influenza vaccine,” Vaccine, vol. 21, no. 16, pp. 1776–1779, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. WHO, “Recommendations for the production and control of influenza vaccine (inactivated),” WHO Tech. Rep. Series 927, 2005. View at Google Scholar
  46. Y. Genzel and U. Reichl, “Continuous cell lines as a production system for influenza vaccines,” Expert Review of Vaccines, vol. 8, no. 12, pp. 1681–1692, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Le Ru, D. Jacob, J. Transfiguracion, S. Ansorge, O. Henry, and A. A. Kamen, “Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing,” Vaccine, vol. 28, no. 21, pp. 3661–3671, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. G. F. Rimmelzwaan, M. Baars, E. C. J. Claas, and A. D. M. E. Osterhaus, “Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro,” Journal of Virological Methods, vol. 74, no. 1, pp. 57–66, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. J. T. M. Voeten, R. Brands, A. M. Palache et al., “Characterization of high-growth reassortant influenza A viruses generated in MDCK cells cultured in serum-free medium,” Vaccine, vol. 17, no. 15-16, pp. 1942–1950, 1999. View at Publisher · View at Google Scholar · View at Scopus
  50. M. G. Pau, C. Ophorst, M. H. Koldijk, G. Schouten, M. Mehtali, and F. Uytdehaag, “The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines,” Vaccine, vol. 19, no. 17–19, pp. 2716–2721, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. O. Kistner, P. N. Barrett, W. Mundt, M. Reiter, S. Schober-Bendixen, and F. Dorner, “Development of a mammalian cell (Vero) derived candidate influenza virus vaccine,” Vaccine, vol. 16, no. 9-10, pp. 960–968, 1998. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Youil, Q. Su, T. J. Toner et al., “Comparative study of influenza virus replication in Vero and MDCK cell lines,” Journal of Virological Methods, vol. 120, no. 1, pp. 23–31, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. A. M. Palache, R. Brands, and G. J. M. van Scharrenburg, “Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs,” Journal of Infectious Diseases, vol. 176, supplement 1, pp. S20–S23, 1997. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Doroshenko and S. A. Halperin, “Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines),” Expert Review of Vaccines, vol. 8, no. 6, pp. 679–688, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Luo, “Egg-independent influenza vaccine: making great strides forward,” Journal of Applied Virology, vol. 2, no. 2, pp. 1–4, 2013. View at Publisher · View at Google Scholar
  56. A. Groener and J. Vorlop, “Animal cells and processes for the replication of influenza viruses,” 1997, http://www.google.com/patents/WO1997037000A1?cl=en.
  57. T. F. Tsai and H. Trusheim, “Making influenza virus vaccines without using eggs,” 2010, http://www.google.com/patents/US20100010199.
  58. European Medicines, Questions and Answers on the Review of Preflucel and Associated Genes, 2012.
  59. P. N. Barrett, W. Mundt, O. Kistner, and M. K. Howard, “Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines,” Expert Review of Vaccines, vol. 8, no. 5, pp. 607–618, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. P. N. Barrett, G. Berezuk, S. Fritsch et al., “Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial,” The Lancet, vol. 377, no. 9767, pp. 751–759, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. H. J. Ehrlich, G. Berezuk, S. Fritsch et al., “Clinical development of a Vero cell culture-derived seasonal influenza vaccine,” Vaccine, vol. 30, no. 29, pp. 4377–4386, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. H. J. Ehrlich, J. Singer, G. Berezuk et al., “A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals,” Clinical Infectious Diseases, vol. 54, no. 7, pp. 946–954, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Vicente, A. Roldão, C. Peixoto, M. J. T. Carrondo, and P. M. Alves, “Large-scale production and purification of VLP-based vaccines,” Journal of Invertebrate Pathology, vol. 107, supplement, pp. S42–S48, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. J. C. King Jr., M. M. Cox, K. Reisinger, J. Hedrick, I. Graham, and P. Patriarca, “Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6–59 months,” Vaccine, vol. 27, no. 47, pp. 6589–6594, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. R. Baxter, P. A. Patriarca, K. Ensor, R. Izikson, K. L. Goldenthal, and M. M. Cox, “Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age,” Vaccine, vol. 29, no. 12, pp. 2272–2278, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. M. M. J. Cox and J. R. Hollister, “FluBlok, a next generation influenza vaccine manufactured in insect cells,” Biologicals, vol. 37, no. 3, pp. 182–189, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. J. O. Josefsberg and B. Buckland, “Vaccine process technology,” Biotechnology and Bioengineering, vol. 109, no. 6, pp. 1443–1460, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. M. M. J. Cox and Y. Hashimoto, “A fast track influenza virus vaccine produced in insect cells,” Journal of Invertebrate Pathology, vol. 107, no. supplement, pp. S31–S41, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Shaw, “New technologies for new influenza vaccines,” Vaccine, vol. 30, no. 33, pp. 4927–4933, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. Y. Z. Ghendon, S. G. Markushin, I. I. Akopova et al., “Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine,” Vaccine, vol. 23, no. 38, pp. 4678–4684, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. J. Liu, X. Shi, R. Schwartz, and G. Kemble, “Use of MDCK cells for production of live attenuated influenza vaccine,” Vaccine, vol. 27, no. 46, pp. 6460–6463, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Romanova, D. Katinger, B. Ferko et al., “Live cold-adapted influenza A vaccine produced in Vero cell line,” Virus Research, vol. 103, no. 1-2, pp. 187–193, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. Z. Wei, M. Mcevoy, V. Razinkov et al., “Biophysical characterization of influenza virus subpopulations using field flow fractionation and multiangle light scattering: correlation of particle counts, size distribution and infectivity,” Journal of Virological Methods, vol. 144, no. 1-2, pp. 122–132, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. J. A. Tree, C. Richardson, A. R. Fooks, J. C. Clegg, and D. Looby, “Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains,” Vaccine, vol. 19, no. 25-26, pp. 3444–3450, 2001. View at Publisher · View at Google Scholar · View at Scopus
  75. M. George, M. Farooq, T. Dang, B. Cortes, J. Liu, and L. Maranga, “Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process,” Biotechnology and Bioengineering, vol. 106, no. 6, pp. 906–917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. J. Steel, A. C. Lowen, L. Pena et al., “Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza,” Journal of Virology, vol. 83, no. 4, pp. 1742–1753, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. B. Zhou, Y. Li, J. A. Belser et al., “NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets,” Vaccine, vol. 28, no. 50, pp. 8015–8025, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. H. Akarsu, K. Iwatsuki-Horimoto, T. Noda et al., “Structure-based design of NS2 mutants for attenuated influenza A virus vaccines,” Virus Research, vol. 155, no. 1, pp. 240–248, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. J. Romanova, B. M. Krenn, M. Wolschek et al., “Preclinical evaluation of a replication-deficient intranasal ΔNS1 H5N1 influenza vaccine,” PLoS ONE, vol. 4, no. 6, Article ID e5984, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. V. Wacheck, A. Egorov, F. Groiss et al., “A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1,” Journal of Infectious Diseases, vol. 201, no. 3, pp. 354–362, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. C. López-Macías, E. Ferat-Osorio, A. Tenorio-Calvo et al., “Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico,” Vaccine, vol. 29, no. 44, pp. 7826–7834, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. S. V. Vemula and S. K. Mittal, “Production of adenovirus vectors and their use as a delivery system for influenza vaccines,” Expert Opinion on Biological Therapy, vol. 10, no. 10, pp. 1469–1487, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. K. R. Van Kampen, Z. Shi, P. Gao et al., “Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans,” Vaccine, vol. 23, no. 8, pp. 1029–1036, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. D. E.-C. Tang, R. S. Jennelle, Z. Shi et al., “Overexpression of adenovirus-encoded transgenes from the cytomegalovirus immediate early promoter in irradiated tumor cells,” Human Gene Therapy, vol. 8, no. 17, pp. 2117–2124, 1997. View at Publisher · View at Google Scholar · View at Scopus
  85. W. Peters, J. R. Brandl, J. D. Lindbloom et al., “Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans,” Vaccine, vol. 31, no. 13, pp. 1752–1758, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Gurwith, M. Lock, E. M. Taylor et al., “Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a Randomised, double-blind, placebo-controlled, phase 1 study,” The Lancet Infectious Diseases, vol. 13, no. 3, pp. 238–250, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. R. D. Antrobus, L. Coughlan, T. K. Berthoud et al., “Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens,” Molecular Therapy, vol. 22, no. 3, pp. 668–674, 2013. View at Publisher · View at Google Scholar
  88. S. V. Vemula, Y. S. Ahi, A.-M. Swaim et al., “Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness,” PLoS ONE, vol. 8, no. 4, Article ID e62496, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. J. Zhang, E. B. Tarbet, T. Feng, Z. Shi, K. R. van Kampen, and D.-C. C. Tang, “Adenovirus-vectored drug-vaccine duo as a rapid-response tool for conferring seamless protection against influenza,” PLoS ONE, vol. 6, no. 7, Article ID e22605, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. J. Alexander, S. Ward, J. Mendy et al., “Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin,” PLoS ONE, vol. 7, no. 2, Article ID e31177, 2012. View at Publisher · View at Google Scholar · View at Scopus
  91. M. A. Croyle, D. J. Anderson, B. J. Roessler, and G. L. Amidon, “Development of a highly efficient purification process for recombinant adenoviral vectors for oral gene delivery,” Pharmaceutical Development and Technology, vol. 3, no. 3, pp. 365–372, 1998. View at Publisher · View at Google Scholar · View at Scopus
  92. D. C. C. Tang, J. Zhang, H. Toro, Z. Shi, and K. R. Van Kampen, “Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines,” Expert Review of Vaccines, vol. 8, no. 4, pp. 469–481, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. C. F. Shen, S. Lanthier, D. Jacob et al., “Process optimization and scale-up for production of rabies vaccine live adenovirus vector (AdRG1.3),” Vaccine, vol. 30, no. 2, pp. 300–306, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Kamen and O. Henry, “Development and optimization of an adenovirus production process,” Journal of Gene Medicine, vol. 6, supplement 1, pp. S184–S192, 2004. View at Publisher · View at Google Scholar · View at Scopus